ERBB2 and breast cancer: In the advanced setting, a better OS has been evidenced for HER2-low BC in comparison with HER2-0 BC in a cohort of 15.054 patients with HER2-negative BC, and the findings were seen in the HR-negative subgroup, although smaller cohorts have not demonstrated a significant difference [90,101,102].